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The incidence and prevalence of diabetes in youth in the United States is increasing. In 
particular, type 2 diabetes mellitus (T2DM) is becoming more common in individuals younger 
than 20 years. Nurse practitioners and other primary care providers that see children should be 
knowledgeable about the condition and confident in participating in multidisciplinary 
management. Screening should begin at age 10 or at puberty, whichever comes first. Providers 
should screen all children who are overweight or obese or of Native American, African 
American, Latino, Asian American, or Pacific Islander race or ethnicity. Children of these 
ethnicities have a greater risk for developing T2DM. Screening and diagnostic tests include 
fasting plasma glucose, the oral glucose tolerance test, and hemoglobin A1C. Once T2DM is 
diagnosed, management should focus on intensive lifestyle changes and weight loss with dietary 
changes and increased physical activity. Initial pharmacological treatment involves an oral 
antihyperglycemic agent and/or subcutaneous insulin therapy. Effective management of a child 
or adolescent with diabetes involves the creation of a multidisciplinary team consisting of an 
endocrinologist, social worker, diabetic educator, dietician, school personnel, psychologist, and 
the family. The family should participate in all aspects of care and commit to making lifestyle 
changes with the patient. As most youth diagnosed with T2DM are adolescents, they should be 
encouraged to practice independent care to enable successful transition to young adulthood. 
Providers should practice culturally sensitive care and individualize treatment and management 
plans for each patient.  
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Type 2 Diabetes Mellitus in the Pediatric Population 
 Pediatric diabetes mellitus is on the rise. Both type 1 and type 2 are increasing in youth. 
The Centers for Disease Control (CDC, 2020) reports that an estimated 210,000 children and 
adolescents younger than 20 years old had diabetes by 2018. The SEARCH study is a national, 
ongoing study with multiple centers participating in research to discover new information 
regarding diabetes and youth. Information from the SEARCH study revealed increasing rates of 
diabetes among youth in the United States (US), especially among youth of minority racial and 
ethnic groups. From 2001 to 2009, the prevalence of type 1 diabetes mellitus (T1DM) increased 
by 21.1% while type 2 diabetes mellitus (T2DM) increased by 30.5% in most age, sex, and race 
or ethnicity groups (Dabelea, et al., 2014; Hamman et al., 2014). From 2002 to 2012, the annual 
increase in incidence was 1.8% for T1DM and 4.8% for T2DM (Mayer-Davis et al., 2017; 
Jensen & Dabelea, 2018). These results provide evidence of the increase of diabetes in youth and 
should not be overlooked. In particular, T2DM has become a more common condition in 
individuals younger than 20 over the last two decades, likely due to an increase in childhood 
obesity. Overweight and obesity are major risk factors for T2DM, and the prevalence and 
incidence of pediatric diabetes has increased in association with the rise of childhood obesity 
(Arslanian et al., 2018; Galuska et al., 2018; Dabelea et al., 2015; Narasimhan & Weinstock, 
2014). Due to the increasing amount of overweight and obese children in the US, nurse 
practitioners (NPs) and other primary care providers (PCPs) who care for children should be 
aware and knowledgeable of diabetic conditions. The purpose of this article is to discuss the 
current screening guidelines, presentation, diagnosis, treatment, and multidisciplinary 
management of T2DM in youth. 
Background 
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 T2DM was previously thought to be a chronic disease seen only in adults; however, an 
increasing number of youths are developing insulin resistance and being diagnosed as type 2 
diabetics. As in adults, T2DM is characterized by insulin resistance rather than an autoimmune 
process that leads to the destruction of beta cells. Type 1 diabetics will typically have 
autoantibodies present at the time of diagnosis and require insulin treatment to survive (Dabelea 
et al., 2015; Barrett, 2016; Xu & Verre, 2018; Zeitler et al., 2018). Type 2 diabetics will not 
typically have autoantibodies and will still have the ability to produce insulin despite insulin 
resistance and pancreatic beta cell failure. These cellular impairments are likely brought on by 
puberty and hormonal changes as well as genetic, environmental, or lifestyle factors, such as 
poor diet, lack of physical activity, and overweight or obesity; hence, the increasing rates of both 
childhood obesity and diabetes (Dabelea et al., 2015; Barrett, 2016; Arslanian et al., 2018; 
Zeitler et al., 2018).  
 Although there are distinct differences between type 1 and type 2 diabetes, it is important 
to note that it has become increasingly difficult to distinguish and diagnose children with the 
correct diabetes type. Some children will be asymptomatic or have symptoms attributed to both 
types, and it is possible for an overweight or obese child to have T1DM. Moreover, results from 
the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study found up 
to 9.8% of children with a diagnosis of T2DM to have autoantibodies (Klingensmith et al., 
2010).  
 More often than not, children with T2DM will be overweight or obese and may already 
have other comorbidities related to an increased body mass index (BMI), such as hypertension or 
dyslipidemia. Furthermore, these youth are at higher risk for developing complications or other 
comorbidities due to diabetes as T2DM in youth leads to a more rapid progression of 
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comorbidities and risk for complications as compared to adults and other youth with T1DM 
(Dabelea et al., 2015; Barrett, 2016; Xu & Verre, 2018; Zeitler et al., 2018).  
Presentation, Screening, and Diagnosis 
 Children with diabetes can be symptomatic or asymptomatic. Symptomatic children may 
present with the classic symptoms of polyuria, polydipsia, and unintentional weight loss, 
accompanied with or without nausea, vomiting, and dehydration. Metabolic disturbances, 
diabetic ketoacidosis, or hyperosmolar states may also be present at the time of diagnosis. The 
American Academy of Pediatrics (AAP) recommends symptomatic children to be tested for 
ketosis with either serum or urine ketones and evaluating for ketoacidosis by obtaining a venous 
pH level (Copeland et al., 2013). Asymptomatic children may be diagnosed from incidental 
findings of screening tests done due to the presence of diabetic risk factors (Klingensmith et al., 
2016; Xu & Verre, 2018). Additional signs or conditions related to insulin resistance include 
acanthosis nigricans, hypertension, hyperlipidemia, polycystic ovary syndrome, or small-for-
gestational-age birth weight (Arslanian et al., 2018). 
 NPs and other providers should screen all children with risk factors for diabetes as well 
as children presenting with signs and symptoms of diabetes. When screening, it is important to 
note that the onset of T2DM prior to puberty is rare, and nearly all youth in North America 
diagnosed with the condition are overweight or obese (Arslanian et al., 2018). The American 
Diabetes Association ([ADA], 2020a) recommends screening to begin at age 10 or at the onset of 
puberty, depending on whichever comes first, and if the child is overweight or obese with one or 
more of the following factors: a maternal history of diabetes or gestational diabetes mellitus 
during the child’s gestation, a family history of T2DM in a first or second degree relative, and 
Native American, African American, Latino, Asian American, or Pacific Islander race or 
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ethnicity. It should be noted that children of these ethnicities have a higher risk for developing 
T2DM (Mayer-Davis et al., 2014; Jensen & Dabelea, 2018). 
  The ADA (2020b) and International Society of Pediatric and Adolescent Diabetes 
([ISPAD], 2018) recommend three different tests for diabetes screening: fasting plasma glucose 
(FPG), oral glucose tolerance test (OGTT), and hemoglobin A1C (HbA1c). These tests may be 
used for both screening and diagnosis. Diagnosis will require two abnormal tests results from the 
same samples or two separate samples. If two different tests are performed (i.e. HbA1c and 
FPG), and both indicate diabetes, this can also confirm the diagnosis (ADA, 2020b).  
FPG is a convenient one-time blood draw. It does require fasting for at least 8 hours prior 
to testing.  
The OGTT requires fasting, as well as additional time to perform the test. Providers 
should follow the World Health Organization (WHO) guidelines and use a glucose load of 
1.75mg/kg (or a maximum of 75 grams) anhydrous glucose dissolved in water. After 2 hours of 
ingesting the solution, plasma glucose should be checked.  
HbA1c is also a convenient one-time blood draw and does not require fasting or 
additional time to perform the test. Additionally, this test may be more sensitive and specific for 
detecting diabetes when compared to the OGTT (Ehehalt et al., 2017). All HbA1c tests should be 
performed in a laboratory using a method that is National Glycohemogloblin Standardization 
Program (NGSP) certified and standardized to the Diabetes Control and Complications Trial 
(DCCT) assay for reliable and accurate results. Despite the benefits and standardization of the 
test, there are multiple factors that can affect a child’s HgbA1c level including ethnicity, age, 
medications, hemoglobinopathies, and disorders that affect red blood cell turnover (Vajravelu & 
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Lee, 2018). Providers suspecting diabetes should keep this in mind when interpreting HbA1c 
results.  
 The ADA (2020b) criteria for the diagnosis of prediabetes and diabetes are the same for 
children, adolescents, and adults. The criteria for diagnosing prediabetes includes the following: 
HbA1c 5.7% to 6.5%, FPG greater than or equal to 100 mg/dL but less than 126 mg/dL, and 2-
hour plasma glucose greater than or equal to 140 mg/dL but less than 200 mg/dL during an 
OGTT. The criteria for diagnosing diabetes is HbA1c greater than or equal to 6.5%, FPG greater 
than or equal to 126 mg/dL, 2-hour plasma glucose greater than or equal to 200 mg/dL during an 
OGTT, or in a patient with classic symptoms of hyperglycemia a random plasma glucose greater 
than 200 mg/dL. Providers considering a diagnosis of T2DM for their patients should also obtain 
a pancreatic autoantibodies panel to further confirm the diagnosis and exclude T1DM. For 
providers screening at-risk children, tests should be repeated every 3 years at a minimum and 
more frequently if the child has an increasing BMI (ADA, 2020b).  
Treatment 
 The initial treatment of T2DM should involve therapeutic lifestyle changes. In addition to 
dietary changes, adding physical exercise, and education, the AAP recommends that all children 
and adolescents start metformin at the time of diagnosis (Copeland et al., 2013). The ADA 
(2020a) also recommends that those with a HbA1c less than 8.5% and no acidosis or ketosis be 
started on metformin. Metformin is considered the first-line pharmacological treatment for youth 
with T2DM and was previously the only US Food and Drug Administration (FDA) approved 
oral diabetic agent for the pediatric population. Providers should start with 500 to 1000 mg daily 
for 7 to 15 days and titrate the dose up once a week over a period of 3 to 4 weeks, depending on 
the patient’s tolerance. The maximum dose is 1000 mg twice a day (Zeitler et al., 2018). Patients 
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that have a HbA1c greater than 8.5%, with no acidosis, and with or without ketosis should be 
started on both metformin and insulin. Insulin should start at 0.25 to 0.5 units/kg and can be 
titrated up to a maximum of 1.5 units/kg. If optimal glucose levels are not met with both 
metformin and insulin therapy, additional medication may be considered. Liraglutide, a 
glucagon-like peptide-1 receptor agonist, was recently approved for use in children 10 years of 
age and older (FDA, 2019). The ADA (2020a) updated their recommendations to consider the 
use of liraglutide if glycemic targets are not met with metformin and basal insulin, and there is 
no family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. 
 Insulin can later be weaned if glycemic targets are continually met, and the child may 
only need to take metformin. Patients and their families should be performing self-monitored 
blood glucose (SMBG) at home in order to track glycemic levels and measure progress to goals. 
Insulin should be weaned over a period of 2 to 6 weeks, and the dose should be decreased by 10 
to 30% every few days (Zeitler et al., 2018). The goal of treatment should be a HbA1c less than 
7.0%, and glycemic targets and the process of SMBG should be individualized (Panagiotopoulos 
et al., 2018; Arslanian et al., 2018; ADA, 2020a).  
Management 
 Once a diagnosis of T2DM has been made and initial treatment has been completed, it is 
crucial that providers carefully manage the care of these patients. As in adults, T2DM is a 
chronic condition, and excellent management requires participation from multiple disciplines. 
Creating a multidisciplinary team including a primary provider, endocrinologist, social worker, 
diabetic educator, dietician, school personnel, psychologist, and family members may be 
beneficial and enable more effective long-term management (ADA, 2020a). Each discipline has 
a specific role in managing a child with diabetes. 
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  It is essential that providers recommend intensive lifestyle changes with a focus on 
weight loss, including increasing physical activity, and dietary measures. The ADA (2020a) 
recommends a family lifestyle change involving the parents or caregivers in nutrition counseling, 
incorporating physical activity, and understanding medical management (such as using insulin or 
metformin) in order to successfully manage and guide the child. As youth with T2DM are 
typically nearing or are of adolescence, they should be educated and encouraged to participate in 
independent care; this includes SMBG, understanding appropriate dietary habits, participating in 
daily physical activity, and knowing signs and symptoms of hypoglycemia or hyperglycemia. 
Diabetic educators can be especially helpful in educating the patient and family in ways that are 
easy for them to understand and retain the information and providing them with resources 
(Galuska et al., 2018).  
Dietary Changes 
 As most youth with T2DM are overweight or obese, weight loss should be the primary 
focus of management. Dieticians who are knowledgeable about T2DM in youth should be 
involved in nutrition counseling for these families. Recommendations include replacing sugary 
beverages, such as soda or juice, with water and calorie-free beverages, increasing fruit and 
vegetable intake, reducing consumption of processed or prepackaged foods, and exchanging high 
caloric and high fat foods for more nutrient-dense, low-caloric options. Dietary interventions 
should be family centered and everyone in the household should be making the same changes 
together in order to encourage the patient to create and sustain healthy eating habits. Parents or 
caregivers should also be educated on healthy diet choices and how to read nutrition labels. 
Dieticians or diabetic educators should educate families in a culturally sensitive matter taking 
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into account food preferences and providing appropriate options and/or substitutions (Xu & 
Verre, 2018; Zeitler et al., 2018).  
Physical Activity 
 Adding or increasing the amount of physical activity is another necessary lifestyle change 
for young diabetics. Thirty to sixty minutes of moderate to vigorous activity daily is 
recommended and can be split into multiple activities during the day (Arslanian et al., 2018; 
Zeitler et al., 2018). Families should be involved in this lifestyle change as well, with at least one 
family member available to participate in the activity with the child and provide encouragement. 
Activities such as taking the stairs instead of the elevator, parking far from a store entrance to 
increase walking, walking to school or the store if nearby, or doing household chores or yard 
work are ways to incorporate more daily physical activity. Screen time should also be kept to a 
two-hour minimum to decrease sedentary lifestyle (Zeitler et al., 2018).  
Psychosocial Factors 
 Racial or ethnic minority groups account for the majority of youth with T2DM (Hamman 
et al., 2014; Mayer-Davis et al., 2017). Providers should recognize potential social issues and 
understand that finances, housing or living conditions, food instability, limited access to services, 
or cultural barriers may cause difficulties in management for the patient and family (ADA, 
2020a; Arslanian et al., 2018). Providers should be sensitive to these stressors and personalize 
care while providing appropriate resources. Social workers are an important part of the 
multidisciplinary team and can provide additional assistance and resources to the family.  
 Providers should also assess the patient’s psychosocial status. The diagnosis of T2DM 
leads to some overwhelming lifestyle changes for a family, and especially for the patient. 
Adolescents with T2DM reported more feelings of depression and a lower quality of life when 
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compared to those with T1DM (Hood et al., 2014). Assessing the patient’s coping skills and 
mental health is another necessary component for proper management; psychologists may also 
be part of the multidisciplinary team for further evaluation and additional help.  
 In addition to socioeconomic or environmental stressors, most of the youth with T2DM 
are adolescents and may have additional stressors. Adolescents in particular are subject to 
increased social or psychological stressors that may increase participation in risky behaviors such 
as tobacco or alcohol use or unprotected sex. Individuals should be counseled on smoking and 
alcohol use, and females should be educated on contraceptive use to avoid pregnancy (Zeitler et 
al., 2018).  
Complications 
 While metformin is the appropriate pharmacological treatment for T2DM, the TODAY 
study found that glycemic control was maintained for only about half of the patients on 
metformin monotherapy. This suggests that T2DM in youth is much more aggressive and can 
lead to the development of complications early on, if not properly managed (Narasimhan & 
Weinstock, 2014). Potential complications include nephropathy, neuropathy, retinopathy, non-
alcoholic fatty liver disease (NAFLD), obstructive sleep apnea (OSA), polycystic ovary 
syndrome (POS), cardiovascular disease, and dyslipidemia. Some of these conditions may be 
present at diagnosis. The ADA (2020a) recommends obtaining blood pressure measurements, a 
fasting lipid panel, liver enzyme panel, and urine albumin to creatinine ratio (ACR) at the time of 
diagnosis. A dilated eye exam and foot exam should also be performed at the time of diagnosis 
or soon after (ADA, 2020a).  
 Blood pressure (BP) should be measured at each visit and should not be greater than the 
90th percentile for age, sex, and height. Lifestyle interventions to lose weight should be 
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encouraged for adolescents aged 13 years and older with a BP greater than 120/80 mmHg. If 
there is no change with intervention after 6 months, antihypertensive therapy should be started 
with angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ADA, 2020a).  
 Desired levels of lipids for children and adolescents are as follows: low density lipid 
(LDL) cholesterol less than 100 mg/dL, high density lipid cholesterol greater than 35 mg/dL, and 
triglycerides less than 150 mg/dL. Measures for controlling lipid levels should focus on blood 
glucose control and dietary measures. If LDL remains above the target goal after 6 months of 
lifestyle interventions, statin therapy should be started. If lipids are at goal, they should be 
checked annually (ADA, 2020a).  
 Albuminuria may be present for many adolescents at the time of diagnosis. In the 
TODAY study (2013), 6.3% of youth had microalbuminuria at baseline, but this number rose to 
16.6% after follow-up at the end of the study. An elevated urine ACR should be obtained at 
diagnosis and confirmed with two out of three samples. Estimated glomerular filtration rate 
(GFR) should also be obtained at time of diagnosis. Providers should monitor kidney function 
and recheck urine ACR and estimated GFR in pediatric patients annually (ADA, 2020a).  
 A dilated eye exam should be performed at the time of diagnosis or as soon as possible to 
evaluate for retinopathy. Comprehensive foot examinations with monofilaments should also be 
performed to assess for neuropathy. Screening for retinopathy and neuropathy should be 
completed annually, and prevention for both retinopathy and neuropathy involve optimizing 
blood glucose levels (ADA, 2020a).  
 Lastly, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) should be 
obtained at the time of diagnosis to evaluate for NAFLD and non-alcoholic steatohepatitis. 
Weight loss can improve these conditions; however, persistently elevated liver enzymes may 
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warrant a referral to a gastroenterologist. An ALT and AST should also be obtained annually 
(ADA, 2020a).  
Future Implications 
 Pediatric diabetes continues to be a growing issue. As T2DM continues to increase in 
youth, providers should be knowledgeable about evidence-based screening, diagnosis, and 
management. Distinguishing between diabetes phenotypes can be difficult, but providers should 
be thorough in their assessments in order to start appropriate treatment. The foundation of 
treatment and management should be based on lifestyle changes to promote weight loss and 
healthy habits. Proactively involving the family in intensive lifestyle changes can improve 
chances for achieving optimal glucose levels and proper management early on to help prevent 
long term complications. Adolescents should be encouraged to be independent in their diabetes 
management in order to be successful during the transition to young adulthood. Care should 
always be individualized, culturally sensitive, and involve multidisciplinary team members. 
While the amount of information and research on pediatric diabetes continues to increase, future 
studies should continue to explore ways to prevent or reduce the risks and complications of 
developing T2DM, including any lifestyle and pharmacological interventions that may best treat 











American Diabetes Association. (2020a). 13. Children and adolescents: Standards of medical  
care in diabetes – 2020. Diabetes Care, 43(Suppl. 1), S163-S182. 
 doi:https://doi.org/10.2337/dc20-S013 
American Diabetes Association. (2020b). 2. Classification and diagnosis of diabetes: Standards  
            of medical care in diabetes – 2020. Diabetes Care, 43(Suppl. 1), S14-S31. 
            doi:https://doi.org/10.2337/dc20-S002 
Arslanian, S., Bacha, F., Grey, M., Marcus, M. D., White, N. H., & Zeitler, P. (2018). Evaluation 
 and management of youth-onset type 2 diabetes: A position statement by the American 
 Diabetes Association. Diabetes Care, 41(12), 2648-2668. 
 doi:https://doi.org/10.2337/dci18-0052 
Barrett, T. (2016). Type 2 diabetes mellitus: incidence, management and prognosis. Paediatrics 
 and Child Health, 27(4), 166-170. doi:https://doi.org/10.1016/j.paed.2016.12.006 
Candler, T., Rinn, S., & Hamilton-Shield, J. (2018). A practical guide to management of 
 youth-onset type 2 diabetes. Journal of Diabetes Nursing, 22(5), 1-8.  
Centers for Disease Control and Prevention. (2020). National diabetes statistics report 2020: 
 Estimates of diabetes and its burden in the United States. Retrieved from: 
 https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf 
Copeland, K. C., Silverstein, J., Moore, K. R., Prazar, G. E., Raymer, T., Shiffman, R. N.,  
Springer, S. C., Thaker, V. V., Anderson, M., Spann, S. J., & Flinn, S. K. (2013). Clinical 
practice guideline: Management of newly diagnosed type 2 diabetes mellitus (T2DM) in 
children and adolescents. Pediatrics, 131(2), 364-382. doi:10.1542/peds.2012-3494 
T2DM IN PEDIATRICS  
 
15 
Dabelea, D., Mayer-Davis, E. J., Saydah, S., Imperatore, G., Linder, B., Divers, J., Bell, R., 
 Badaru, A., Talton, J. W., Crume, T., Liese, A. D., Merchant, A. T., Lawrence, J. M., 
 Reynolds, K., Dolan, L., Liu, L. L., Hamman, R. F. (2014). Prevalence of type 1 and type 
 2 diabetes among children and adolescents from 2001 to 2009. JAMA, 311(17), 1778–
 1786. doi:https://doi.org/10.1001/jama.2014.3201 
Dabelea, D., Hamman, R. F., & Knowler, W. C. (2015). Chapter 15: Diabetes in youth. In 
 Cowie, C. C., Casagrande, S. S., Menke, A., Cissell, M. A., Eberhardt, M. S., Meigs. J. 
 B., Gregg, E. W., Knowler, W. C., Barrett-Connor, E., Becker, D. J., Brancati, F. L., 
 Boyko, E. J., Herman, W. H., Howard, B. V., Narayan, K. M. V., Rewers, M., Fradkin, J. 
 E., (Eds.), Diabetes in America (3rd ed.). (pp. 15-1 – 15-44). National Institutes of 
 Health, NIH Pub No. 17-1468. 
Ehehalt, S., Wiegand, S., Körner, A., Schweizer, R., Liesenkötter, K., Partsch, C., Blumenstock, 
 G., Spielau, U., Denzer, C., Ranke, M. B., Neu, A., Binder, G., Wabitsch, M., Kiess, W., 
 & Reinehr, T. (2017). Diabetes screening in overweight and obese children 
 and adolescents: choosing the right test. European Journal of Pediatrics, 176, 89-97. 
 doi:10.1007/s00431-016-2807-6 
Food and Drug Administration. (2019, September 9). FDA approves 2 products to treat diabetes 
 in pediatric patients. AAP News. 
 https://www.aappublications.org/news/2019/09/09/fdaupdate090919 
Galuska, D. A., Gunn, J. P., O’Connor, A. E., & Peterson, R. (2018). Addressing childhood 
 obesity for type 2 diabetes prevention: Challenges and opportunities. Spectrum Diabetes, 
 31(4), 330-335. doi:https://doi.org/10.2337/ds18-0017 
T2DM IN PEDIATRICS  
 
16 
Gandica, R. & Zeitler, P. (2016). Update on youth-onset type 2 diabetes: Lessons learned from 
 the TODAY clinical trial. Advanced Pediatrics, 63(1), 195-209. 
 doi:10.1016/j.yapd.2016.04.013. 
Gonzalez, K. E. & Freysteinson, W. (2019). Youth-onset type 2 diabetes mellitus in primary 
 practice: A review. Pediatric Nursing, 45(6), 293-296.  
Hamman, R. F., Bell, R. A., Dabelea, D., D’Agostino, R. B. Jr., Dolan, L., Imperatore, G., 
 Lawrence, J. M, Linder, B. Marcovina, S. M., Pihoker, C., Rodriguez, B. L., & Saydah, 
 S. (2014). The SEARCH for diabetes in youth study: Rationale, findings, and future 
 directions. Diabetes Care, 37, 3336–3344. doi:10.2337/dc14-0574 
Hood, K. K., Beavers, D.P., Yi-Frazier, J., Bell, R., Dabelea, D., Mckeown, R. E., & Lawrence, 
 J. M. (2014). Psychosocial burden and glycemic control during the first 6 years of  
 diabetes: results from the SEARCH for diabetes in youth study. Journal of Adolescent 
 Health, 55(4), 498-504. doi:10.1016/j.jadohealth.2014.03.011 
Jensen, E. T. & Dabelea, D. (2018). Type 2 diabetes in youth: New lessons from the SEARCH 
 study. Current Diabetes Reports, 18, 36. doi:https://doi.org/10.1007/s11892-018-0997-1 
Klingensmith, G. J., Pyle, L., Arslanian, S., Copeland, K. C., Cuttler, L., Kaufman, F., Laffel, L., 
 Marcovina, S., Tollefsen, S. E., Weinstock, R. S., & Linder, B. (2010). The presence of 
 GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype. Diabetes Care, 
 33(9), 1970-1975. doi:10.2337/dc10-0373 
Klingensmith, G. J., Connor, C. G., Ruedy, K. J., Beck, R. W., Kollman, C., Haro, H., Wood, J. 
 R., Lee, J. M., Willi, S. M., Cengiz, E., & Tamborlane, W. V. (2016). Presentation of 
 youth with type 2 diabetes in the pediatric diabetes consortium. Pediatric Diabetes, 17, 
 266-273. doi:10.1111/pedi.12281 
T2DM IN PEDIATRICS  
 
17 
Mayer-Davis, E. J., Lawrence, J. M., Dabelea, D., Divers, J., Isom, S., Dolan, L., Imperatore, G., 
 Linder, B., Marcovina, S., Pettitt, D. J., Pihoker, C., Saydah, S., & Wagenknecht, L. 
 (2017). Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. The 
 New England Journal of Medicine, 376(15), 1419-1429. doi:10.1056/NEJMoa1610187 
Narasimhan, S. & Weinstock, R. S. (2014). Youth-onset type 2 diabetes mellitus: Lessons 
 learned from the TODAY study. Mayo Clinic Proceedings, 89(6), 806-816. doi: 
 http://dx.doi.org/10.1016/j.mayocp.2014.01.009 
Panagiotopoulos, C., Hadjiyannakis, S., & Henderson, M. (2018). Type 2 diabetes in children 
 and adolescents. Canadian Journal of Diabetes, 42, S247-S254. 
 doi:https://doi.org/10.1016/j.jcjd.2017.10.037 
TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: 
 the TODAY clinical trial [published correction appears in Diabetes Care. 2013 
 Aug;36(8):2448]. Diabetes Care. 2013;36(6):1735–1741. doi:10.2337/dc12-2420 
Vajravelu, M. E. & Lee, J. M. (2018). Identifying prediabetes and type 2 diabetes in 
 asymptomatic youth: Should HbA1c be used as a diagnostic approach? Current Diabetes 
 Reports, 18(43), 1-10. doi:https://doi.org/10.1007/s11892-018-1012-6 
Xu, H. & Verre, M. C. (2018). Type 2 diabetes mellitus in children. American Family Physician, 
 98(9), 590-594.  
Zeitler, P., Arslanian, S., Fu, J., Pinhas-Hamiel, O., Reinehr, T., Tandon, N., Urakami, T., Wong, 
 J., & Maahs, D. M. (2018). ISPAD clinical practice consensus guidelines 2018: Type 2 
 diabetes mellitus in youth. Pediatric Diabetes, 19(Suppl. 27), 28-46. 
 doi:10.1111/pedi.12719 
 
